
By: Pierre Regibeau (Vox)
On 15 December 2020, the European Commission approved the acquisition of Fitbit by Alphabet, subject to a number of commitments (European Commission 2020). Once a leader in the design and production of fitness trackers, Fitbit had seen its worldwide market share of the overall smartwatch segment fall to between 5% and 10% and was for sale. By acquiring Fitbit, Google would get access to the company’s product, data about the health and health habits of Fitbit users, and Fitbit’s expertise in designing efficient sensor technology for digital wear.
This case caused considerable agitation among some academic and policy circles and led to a number of contributions pressing the Commission to block the transaction (Caffarra and Valletti 2020, Bria et al. 2020, Caffarra and Crawford 2020, Privacy International 2019). The image conveyed by these contributions is apocalyptic: access to Fitbit data would help Google further dominate the market for online advertising and the synergies between these data and the data that Google already holds would ensure its eventual dominance in digital health. This would have dire consequences for privacy. Finally, the acquisition would reduce Google’s incentives to keep its Android ecosystem open to rival wearable products.
I believe that the discussion should now move from the realm of speculation to the sphere of evidence. It is in this spirit that I would like to explain why I find the Commission’s decision fully appropriate. What follows is my own, simplified, view of the economics of the case, stripped of its jargon, legal strappings and subtleties.
The role and standards of merger review
Merger review is meant to ensure that mergers and acquisitions do not hurt consumers by increasing prices, decreasing quality, limiting variety or dampening innovation. These potential harmful effects are evaluated by comparing the post-merger situation to the counterfactual, i.e. to the situation that would have prevailed without the merger…
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas